Compare Cardinal Health Inc (CAH) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Lam Research Corporation — how do they compare? Cardinal Health Inc trades at $234.16 (market cap $55.88B), while Lam Research Corporation trades at $326.7 (market cap $389.67B). The key difference: Lam Research Corporation is far larger — about 7× Cardinal Health Inc's market cap, and Cardinal Health Inc pays the higher dividend (0.86%). Which is the better fit depends on your goals.
| CAH | LRCX | |
|---|---|---|
Market Cap | $55.88B | $389.67B |
Sector | Health | Technology |
52-Week High | $240.26 | $433.33 |
52-Week Low | $146.04 | $97.03 |
Enterprise Value | $59.91B | $387.83B |
Dividend Yield | 0.86% | 0.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $235.3, down 0.79% on the day, but remains near its 52-week high. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue for fiscal 2025 was $222.58 billion, with net income reaching $1.56 billion. Analyst consensus is strongly positive, with 18 buys and a $266.43 price target, reflecting confidence in the company's pharmaceutical and specialty business growth.
The outlook for CAH is favorable, driven by robust earnings performance and optimistic fiscal 2027 guidance. Key opportunities include sustained demand for specialty drugs and operational efficiency gains. Risks involve high debt levels, with a debt-to-asset ratio of 16.09 in 2025, and competitive pressures in the healthcare distribution sector. Investors should weigh strong analyst support against balance sheet leverage and market volatility.
Lam Research (LRCX) trades at $326.02, up 6.4% in 24 hours, with a bullish technical signal and strong earnings beats. The stock shows robust fundamentals with a 29.06% net income margin and 65.07% ROE in 2025, supported by positive analyst sentiment and expansion into panel-level packaging. Recent news highlights AI-driven semiconductor demand as a key growth catalyst.
Outlook remains positive given consensus price target of $397.18 and 78% buy ratings, though high P/E of 54.06 and competitive pressures from new entrants like SpaceX's Terrafab pose risks. Revenue growth to $23.2B in 2026 suggests sustained momentum, but investors should monitor execution amid industry volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
